Literature DB >> 24736999

Somatostatin analog withdrawal in patients with acromegaly: an elusive goal?

Moisés Mercado1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24736999     DOI： 10.1007/s12020-014-0262-6

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  15 in total

1.  Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas.

Authors:  Paola Luciani; Stefania Gelmini; Emanuele Ferrante; Andrea Lania; Susanna Benvenuti; Silvana Baglioni; Giovanna Mantovani; Ilaria Cellai; Franco Ammannati; Anna Spada; Mario Serio; Alessandro Peri
Journal:  J Clin Endocrinol Metab       Date:  2005-08-09       Impact factor: 5.958

Review 2.  Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia.

Authors:  Alberto M Pereira
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2011-08       Impact factor: 3.243

3.  Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly.

Authors:  Y Lorcy; S Dejager; P Chanson
Journal:  Pituitary       Date:  2000-11       Impact factor: 4.107

4.  Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?

Authors:  Claudia Ramírez; Guadalupe Vargas; Baldomero González; Ashley Grossman; Julia Rábago; Ernesto Sosa; Ana Laura Espinosa-de-Los-Monteros; Moisés Mercado
Journal:  Eur J Endocrinol       Date:  2011-10-12       Impact factor: 6.664

5.  Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas.

Authors:  M Losa; E Ciccarelli; P Mortini; R Barzaghi; D Gaia; G Faccani; M Papotti; F Mangili; M R Terreni; F Camanni; M Giovanelli
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

6.  Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.

Authors:  Nienke R Biermasz; Niels C van den Oever; Marijke Frölich; Alberto M Pereira Arias; Jan W A Smit; Johannes A Romijn; Ferdinand Roelfsema
Journal:  Clin Endocrinol (Oxf)       Date:  2003-03       Impact factor: 3.478

Review 7.  A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.

Authors:  Robert D Murray; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2008-05-13       Impact factor: 5.958

8.  Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial.

Authors:  Lucio Vilar; Maria Fleseriu; Luciana Ansaneli Naves; José Luciano Albuquerque; Patrícia Sampaio Gadelha; Manuel dos Santos Faria; Gilvan Cortês Nascimento; Renan Magalhães Montenegro; Renan Magalhães Montenegro
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 9.  Clinical, quality of life, and economic value of acromegaly disease control.

Authors:  A Ben-Shlomo; M C Sheppard; J M Stephens; S Pulgar; S Melmed
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

10.  The role of primary pharmacological therapy in acromegaly.

Authors:  Ana Laura Espinosa de los Monteros; Carmen A Carrasco; Alfredo Adolfo Reza Albarrán; Mônica Gadelha; Alin Abreu; Moisés Mercado
Journal:  Pituitary       Date:  2014-01       Impact factor: 4.107
View more
  1 in total

1.  Optimal use of pegvisomant in acromegaly: are we getting there?

Authors:  Andrea Giustina
Journal:  Endocrine       Date:  2014-10-28       Impact factor: 3.633
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.